
Ratio Therapeutics Secures Actinium-225 Supply Deal with PanTera
Boston-based clinical-stage developer Ratio Therapeutics has finalized a strategic supply agreement with PanTera to procure Actinium-225, a critical radioisotope for cancer treatment. This partnership aims to fortify the company’s manufacturing infrastructure as it advances its pipeline of targeted alpha therapies for solid tumors.



























